RxDoctor Payments Data

Krithika Iyer, MD

Child & Adolescent Psychiatry · Tamarac, FLNPI 1588753438

Payments from drug & device makers

$1,453in general payments, 2019–2025

Across 33 payments — averaging $44.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$287
  • Sunovion Pharmaceuticals Inc.$258
  • Neurocrine Biosciences, Inc.$211
  • Johnson & Johnson$176
  • Teva Pharmaceuticals USA, Inc.$146
  • Novo Nordisk$125
  • plus $250 from 6 others

What the payments were for

  • Food & beverage$1,42698%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,453 in reported general payments places this provider in the 65th percentile of 206 child & adolescent psychiatry providers in Florida.

See all child & adolescent psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$36,072
Medicare patients
104
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide13$6,331
Aripiprazole43$6,101
Duloxetine Hcl32$723
Quetiapine Fumarate48$692
Risperidone29$614
Alprazolam67$558
Clonazepam57$487
Gabapentin57$439
Bupropion XlBupropion Hcl19$431
Olanzapine30$430
Methylphenidate Hcl13$371
Trazodone Hcl42$363
Sertraline Hcl26$314
Divalproex Sodium15$311
Mirtazapine21$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$29$31426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 206 child & adolescent psychiatry providers in Florida.

Other child & adolescent psychiatry in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →